BRIEF-Mineralys Therapeutics Announces Mid-Stage Study Of Lorundrostat For Obstructive Sleep Apnea In Patients With Hypertension

Reuters
08 Jan

Jan 8 (Reuters) - Mineralys Therapeutics Inc :

* MINERALYS THERAPEUTICS ANNOUNCES PHASE 2 CLINICAL TRIAL OF LORUNDROSTAT FOR OBSTRUCTIVE SLEEP APNEA IN PATIENTS WITH HYPERTENSION

* MINERALYS THERAPEUTICS INC - TO INITIATE PHASE 2 TRIAL IN Q1 2025

* MINERALYS THERAPEUTICS INC - EXPECTS FUNDS TO SUPPORT OPERATIONS THROUGH Q1 2026

* MINERALYS THERAPEUTICS INC - PRIMARY OUTCOME MEASURE IS CHANGE IN APNEA-HYPOPNEA EPISODES

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10